Claims for Patent: 10,537,584

Summary for Patent: 10,537,584

Title:	Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof
Abstract:	The present invention relates to monolithic intravaginal rings comprising progesterone, methods of making, and uses thereof. The intravaginal rings comprise progesterone, a polysiloxane elastomer, and a pharmaceutically acceptable hydrocarbon or glycerol esters of a fatty acid.
Inventor(s):	Ahmed; Salah U. (New City, NY), Tsao; Jiaxiang (Nanuet, NY), Mahashabde; Anu (Kendall Park, NJ), Harrison; Diane D. (Villanova, PA)
Assignee:	FERRING B.V. (Hoofddorp, NL)
Application Number:	15/176,169
Patent Claims:	1. A monolithic intravaginal ring for treating a luteal phase defect in a patient in need thereof, the ring comprising: (a) about 10% to about 30% by weight of progesterone; (b) about 60% to about 80% by weight of polysiloxane elastomer; and (c) about 1% to about 8% by weight of a pharmaceutically acceptable hydrocarbon or glycerol esters of a fatty acid or pharmaceutically acceptable oil, wherein the progesterone is homogeneously dispersed in the elastomer. 2. The monolithic intravaginal ring of claim 1, wherein the polysiloxane elastomer is a diorganopolysiloxane elastomer. 3. The monolithic intravaginal ring of claim 2, wherein the diorganopolysiloxane elastomer is dimethylpolysiloxane elastomer. 4. The monolithic intravaginal ring of claim 1, wherein the ring further comprises a second polysiloxane. 5. The monolithic intravaginal ring of claim 4, wherein the second polysiloxane is a crosslinker. 6. The monolithic intravaginal ring of claim 5, wherein the crosslinker is dimethylmethylhydrogen polysiloxane. 7. The monolithic intravaginal ring of claim 1, wherein the progesterone is present in an amount of about 15% to about 30% by total weight of the ring. 8. The monolithic intravaginal ring of claim 1, wherein the ring is constructed to release the progesterone at a steady rate for about 1 day to about 14 days. 9. The monolithic intravaginal ring of claim 1, wherein the ring is constructed to release the progesterone at a steady rate for about 1 day to about 10 days. 10. The monolithic intravaginal ring of claim 1, wherein the ring is constructed to release the progesterone at a steady rate for about 1 day to about 7 days. 11. The monolithic intravaginal ring of claim 1, wherein the polysiloxane elastomer is a dimethylpolysiloxane elastomer, and wherein the ratio by weight of progesterone to elastomer is about 1:2 to about 1:5. 12. A monolithic intravaginal ring for treating a luteal phase defect in a patient in need thereof, wherein the intravaginal ring comprises: (a) about 15% to about 25% by weight of the progesterone; (b) about 70% to about 80% by weight of a dimethylpolysiloxane elastomer; and (c) about 1% to about 8% by weight of mineral oil, wherein the progesterone is homogeneously dispersed in the elastomer. 13. The monolithic intravaginal ring of claim 1, wherein the polysiloxane elastomer is vinyl end blocked. 14. The monolithic intravaginal ring of claim 1, wherein the ring is constructed to release the progesterone at about 10 mg/day to about 40 mg/day in vivo. 15. The monolithic intravaginal ring of claim 1, wherein the ring is constructed to release the progesterone at about 10 mg/day to about 30 mg/day in vivo. 16. The monolithic intravaginal ring of claim 1, wherein the ring is constructed to release the progesterone at about 15 mg/day to about 25 mg/day in vivo. 17. The monolithic intravaginal ring of claim 1, wherein the ring comprises the pharmaceutically acceptable oil in an amount of about 1% to about 8% by total weight of the ring. 18. The monolithic intravaginal ring of claim 17, wherein the pharmaceutically acceptable oil is selected from mineral oil, silicone oil and combinations thereof. 19. The monolithic intravaginal ring of claim 17, wherein the pharmaceutically acceptable oil is mineral oil. 20. The monolithic intravaginal ring of claim 1, wherein the intravaginal ring comprises: the progesterone, a dimethylpolysiloxane elastomer, and the pharmaceutically acceptable oil, in a ratio by weight of about 4:15:1, respectively. 21. The monolithic intravaginal ring of claim 1, wherein the ring is constructed to release about 11 mg to about 15 mg progesterone per day at a steady rate for 7 days. 22. The monolithic intravaginal ring of claim 1, wherein the ring is effective to maintain a relatively constant serum progesterone level of from about 6 ng/mL to about 10 ng/ml over a 7-day period of use after administration to subject. 23. The monolithic intravaginal ring of claim 1, wherein the ring comprises about 1% to about 8% by weight mineral oil.